Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts

ACRS•2026-07-15

Cash position and funding outlook

Aclaris reported a cash position of $191 million as of 3/31/26, with planned operations funded through 2028.

2026 pipeline catalysts outlined

Aclaris outlined three 2026 pipeline catalysts across its inflammation and immunology portfolio, centered on TSLP biologics and ITK-focused oral inhibitors.

Bosakitug (ATI-045): Phase 2 atopic dermatitis topline data targeted for 4Q 2026; positioned as higher potency with longer TSLP residence time.
ATI-052: Bispecific TSLP x IL-4Rα Phase 1b proof-of-concept topline readouts in atopic dermatitis and asthma expected in 2H 2026; Phase 2b start slated for 4Q 2026.
Modzatinib (ATI-2138): Phase 2b initiation in lichen planus planned for 2H 2026; ATI-9494 IND submission planned for 2H 2026.

Sources

Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts

Docs

Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts

Cash position and funding outlook

2026 pipeline catalysts outlined

Related News

Pentair shares dip 17% on dour forecast amid weak pool sales

BlackRock portfolio manager Richard M. Rieder acquires $566,740 of BlackRock ESG Capital Allocation Term Trust common shares

U.S. Research Roundup-Equinix, Goldman Sachs, JPMorgan

Sources

Aclaris publishes corporate presentation outlining inflammatory and immunology pipeline, 2026 clinical catalysts

Associated Bank names Matt Krutza Milwaukee private banking group manager

US natgas prices edge up as heat wave lifts power demand for air conditioning